Actualités Fortress Biotech Inc - FBIO | Actions NASDAQ

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults...

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the...

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of...

Mustang Bio Receives Positive Listing Determination from Nasdaq

WORCESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq:...

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing...

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

SCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey...

Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified...

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

WORCESTER, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq:...

Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit

MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the...

Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

SCOTTSDALE, Ariz., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the...

Fortress Biotech to Participate in October 2024 Investor Conferences

MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative...

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements

MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an...

Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference

SCOTTSDALE, Ariz., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the...

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative...

Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SCOTTSDALE, Ariz., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Fortress Biotech Inc (FBIO)

Outils de qualité professionnelle, pour des investisseurs individuels.

FBIO Actualités

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Mustang Bio Receives Positive Listing Determination from Nasdaq

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit

Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Fortress Biotech to Participate in October 2024 Investor Conferences

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements

Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Fortress Biotech Inc (FBIO) Actualités

Fortress Biotech Inc (FBIO)

Outils de qualité professionnelle, pour des investisseurs individuels.

FBIO Actualités

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Mustang Bio Receives Positive Listing Determination from Nasdaq

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit

Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Fortress Biotech to Participate in October 2024 Investor Conferences

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements

Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application